Angiogenesis is an important step in breast cancer (BC) growth and progression. Targeting
angiogenesis was the most interesting by developed strategy in the treatment of HER2-negative BC.
Bevacizumab is a monoclonal humanized antibody targeting the vascular endothelial growth factor
(VEGF) the most potent factor implicated in tumor angiogenesis. It is the most developed targeted agent
in HER2-negative MBC and showed the most interesting results in combination with chemotherapy.
Currently, bevacizumab is the only approved targeted therapy (in Europe only) in the first line treatment
of HER2-negative metastatic BC in combination with weekly paclitaxel. The aim of the present paper is
to review the role of anti-angiogenic agents (targeted agents only) in the treatment of HER2-negative
Keywords: Anti-angiogenic agents, bevacizumab, breast cancer, VEGF, VEGFR.
Rights & PermissionsPrintExport